Targeting the "undruggable" RAS with biologics.

Abstract excerpt

RAS proteins represent critical drivers of tumor development and thus are the focus of intense efforts to pharmacologically inhibit these proteins in human cancer. Although recent success has been attained in developing clinically efficacious inhibitors to KRASG12C, there remains a critical need for developing approaches to inhibit additional mutant RAS proteins. A number of anti-RAS biologics have been developed...

Topics

Join the communities discussing this publication.

• Biological Products
• Mutation
• Neoplasms
• ras Proteins